Dermaliq Therapeutics
Wilmington
About Dermaliq Therapeutics
Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The proprietary technology now owned by Dermaliq, called hyliQ™, is designed to allow cutaneous drug delivery with bioavailability. The technology enables the development of effective liquid drug products with exceptional cosmetic properties.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $15.0M
- Last round: Undisclosed (May 2025)
- Website: dermaliq.com
- Phone: [email protected]
Industries & Categories
Fitness, Health Care, Pharmaceutical, Wellness
Social Profiles
Canonical: https://fsome.com/organization/dermaliq-therapeutics-54224 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.